Sleep Disorders

Vibrance-2 is a double-blind, placebo-controlled trial with 80 participants, assessing three doses of ALKS 2680 over eight weeks

Here's some of what is coming soon to NeurologyLive® this week.

Here's some of what is coming soon to NeurologyLive® this week.

The double-blind, single-dose, 5-period crossover study is expected to include approximately 40 patients with narcolepsy type 1 to test 3 dose strengths of E2086.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on care of idiopathic hypersomnia.

Known as REVITALYZ, the double-blind, placebo-controlled study will assess the effect of once-nightly sodium oxybate on the primary end point of change in Epworth Sleepiness Scale over a 14-week period.

Panelists John England, MD, FAAN, and Lisa Merlin, MD, discuss the main objectives of the upcoming AUPN Annual Meeting, set to take place September 14th in Orlando, Florida.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on congenital muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 26, 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on progressive multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 19, 2024.

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals discussed how sodium oxybate has evolved over the years and the educational aspects of cardiovascular implications patients and clinicians should be aware of. [WATCH TIME: 3 minutes]

Take a look at some of the most-anticipated clinical trials with expected data readouts in the second half of 2024 that researchers and clinicians in neurology should keep an eye out on.

The neurologist and clerkship director at the University of Connecticut provided perspective on the developing role of clerkship directors and the value they provide to neurology departments.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on multiple system atrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 12, 2024.

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of June 2024, compiled all into one place by the NeurologyLive® team.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on headache and nerve decompression surgery.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 5, 2024.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network. for the week ending June 29, 2024. [WATCH TIME: 3 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on epilepsy/Dravet syndrome.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 28, 2024.

In honor of Insomnia Awareness Night, the president of the American Academy of Sleep Medicine board of directors talked about increasing awareness of the sleep disorder for the clinical and patient community. [WATCH TIME: 6 minutes]

The director of the Center for Sleep and Cardiovascular Outcomes Research at University of Pittsburgh talked about a phase 3 trial assessing a pharmaceutical treatment, AD109, in sleep apnea.